
## Katarzyna B Winsz-Szczotka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8892112/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy. Clinica Chimica Acta, 2000, 300, 107-117.	0.5	115
2	Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. Diabetes Research and Clinical Practice, 2005, 68, 207-216.	1.1	41
3	Age- and Gender-Dependent Changes in Connective Tissue Remodeling: Physiological Differences in Circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 Level. Gerontology, 2011, 57, 44-52.	1.4	41
4	Propolis Induces Chondroitin/Dermatan Sulphate and Hyaluronic Acid Accumulation in the Skin of Burned Wound. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-8.	0.5	38
5	Propolis modulates vitronectin, laminin, and heparan sulfate/heparin expression during experimental burn healing. Journal of Zhejiang University: Science B, 2012, 13, 932-941.	1.3	27
6	Plasma biomarkers of oxidative and AGE-mediated damage of proteins and glycosaminoglycans during healthy ageing: A possible association with ECM metabolism. Mechanisms of Ageing and Development, 2012, 133, 538-548.	2.2	22
7	Age-related changes of plasma glycosaminoglycans. Clinical Chemistry and Laboratory Medicine, 2008, 46, 219-24.	1.4	18
8	Relationship between adiponectin, leptin, <scp>IGF</scp> â€1 and total lipid peroxides plasma concentrations in patients with systemic sclerosis: possible role in disease development. International Journal of Rheumatic Diseases, 2016, 19, 706-714.	0.9	18
9	Alterations of glycosaminoglycan metabolism in the development of diabetic complications in relation to metabolic control. Clinical Chemistry and Laboratory Medicine, 2005, 43, 924-9.	1.4	17
10	Age- and gender-related alteration in plasma advanced oxidation protein products (AOPP) and glycosaminoglycan (GAG) concentrations in physiological ageing. Clinical Chemistry and Laboratory Medicine, 2012, 50, 557-63.	1.4	17
11	Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population. Clinical Biochemistry, 2014, 47, 1341-1343.	0.8	16
12	Adiponectin, Leptin, and Leptin Receptor in Obese Patients with Type 2 Diabetes Treated with Insulin Detemir. Molecules, 2017, 22, 1274.	1.7	16
13	Influence of proteolytic–antiproteolytic enzymes and prooxidative–antioxidative factors on proteoglycan alterations in children with juvenile idiopathic arthritis. Clinical Biochemistry, 2014, 47, 829-834.	0.8	13
14	Circulating keratan sulfate as a marker of metabolic changes of cartilage proteoglycan in juvenile idiopathic arthritis; influence of growth factors as well as proteolytic and prooxidative agents on aggrecan alterations. Clinical Chemistry and Laboratory Medicine, 2015, 53, 291-7.	1.4	13
15	Alterations of Extracellular Matrix Components in the Course of Juvenile Idiopathic Arthritis. Metabolites, 2021, 11, 132.	1.3	13
16	Metabolism of glycosaminoglycans in the course of juvenile idiopathic arthritis. Postepy Higieny I Medycyny Doswiadczalnej, 2016, 70, 135-142.	0.1	11
17	Plasma and urinary glycosaminoglycans in the course of juvenile idiopathic arthritis. Biochemical and Biophysical Research Communications, 2015, 458, 639-643.	1.0	10
18	Alterations in serum glycosaminoglycan profiles in Graves' patients. Clinical Chemistry and Laboratory Medicine, 2006, 44, 582-8.	1.4	8

#	ARTICLE	IF	CITATIONS
19	Age- and gender-dependent changes in circulating concentrations of tumor necrosis factor-α, soluble tumor necrosis factor receptor-1 and sulfated glycosaminoglycan in healthy people. Clinical Chemistry and Laboratory Medicine, 2011, 49, 121-127.	1.4	7
20	Antioxidant activity and structural modifications of serum chondroitin sulfate in Graves' disease. Clinical Biochemistry, 2014, 47, 19-24.	0.8	7
21	Laboratory Indicators of Aggrecan Turnover in Juvenile Idiopathic Arthritis. Disease Markers, 2016, 2016, 1-7.	0.6	7
22	Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta. BioMed Research International, 2020, 2020, 1-8.	0.9	7
23	Graves' disease—associated changes in the serum lysosomal glycosidases activity and the glycosaminoglycan content. Clinica Chimica Acta, 2003, 331, 97-102.	0.5	6
24	Urinary sulphated glycosaminoglycans excretion in obese patients with type 2 diabetes mellitus treated with metformin. Archives of Physiology and Biochemistry, 2019, , 1-7.	1.0	5
25	Association of Circulating COMP and YKL-40 as Markers of Metabolic Changes of Cartilage with Adipocytokines in Juvenile Idiopathic Arthritis. Metabolites, 2020, 10, 61.	1.3	4
26	Significant Remodeling Affects the Circulating Glycosaminoglycan Profile in Adult Patients with both Severe and Mild Forms of Acute Pancreatitis. Journal of Clinical Medicine, 2020, 9, 1308.	1.0	4
27	The Effects of TNF-α Inhibition on the Metabolism of Cartilage: Relationship between KS, HA, HAPLN1 and ADAMTS4, ADAMTS5, TOS and TGF-β1 Plasma Concentrations in Patients with Juvenile Idiopathic Arthritis. Journal of Clinical Medicine, 2022, 11, 2013.	1.0	4
28	Concerted Actions by PIICP, CTXII, and TNF-α in Patients with Juvenile Idiopathic Arthritis. Biomolecules, 2021, 11, 648.	1.8	2
29	High-level of circulating progranulin and its relationship with plasma glycosaminoglycans, as biochemical indicators of proteolytic and oxidative aggrecan modification, in the course of juvenile idionathic arthritis. Posterny Higiany I Meducury Doswiadozalnai, 2018, 72, 906-912	0.1	Ο